Alkermes (NASDAQ:ALKS) Issues FY 2025 Earnings Guidance

Alkermes (NASDAQ:ALKS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 1.030-1.210 for the period, compared to the consensus EPS estimate of 1.740. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Alkermes Stock Performance

NASDAQ ALKS opened at $31.96 on Wednesday. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. Alkermes has a 52-week low of $22.90 and a 52-week high of $32.88. The business’s 50-day moving average price is $30.11 and its 200 day moving average price is $28.62. The firm has a market cap of $5.17 billion, a P/E ratio of 16.39, a P/E/G ratio of 1.83 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. On average, equities research analysts expect that Alkermes will post 2.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ALKS shares. Cantor Fitzgerald lowered their price target on Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Deutsche Bank Aktiengesellschaft initiated coverage on Alkermes in a report on Tuesday. They set a “buy” rating and a $40.00 price target on the stock. Piper Sandler restated an “overweight” rating and issued a $37.00 price objective (down previously from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Stifel Nicolaus upgraded shares of Alkermes from a “hold” rating to a “buy” rating and raised their price objective for the company from $25.00 to $36.00 in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Alkermes currently has a consensus rating of “Moderate Buy” and a consensus price target of $36.33.

Insider Activity

In other news, SVP Christian Todd Nichols sold 5,208 shares of Alkermes stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total transaction of $151,813.20. Following the completion of the sale, the senior vice president now directly owns 60,703 shares in the company, valued at approximately $1,769,492.45. This trade represents a 7.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Craig C. Hopkinson sold 9,221 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $31.50, for a total transaction of $290,461.50. Following the transaction, the executive vice president now directly owns 59,730 shares of the company’s stock, valued at approximately $1,881,495. This trade represents a 13.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 179,189 shares of company stock worth $5,723,518. Company insiders own 4.89% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.